Akorn, Inc. (NASDAQ: AKRX)

RM LAW, P.C. has commenced an investigation into potential securities law violations by certain officers of Akorn, Inc. (“Akorn” or the “Company”) (NASDAQ: AKRX).

If you purchased shares of Akorn and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here.

In a recent ruling, a Delaware Court determined that Fresenius SE could walk away from its $4.3 billion deal to buy pharmaceutical manufacturer Akorn. Soon after the parties signed the deal documents, Akorn’s financials slumped dramatically. When Fresenius found that Akorn had breached U.S. Food and Drug Administration data integrity requirements, the company terminated the deal due to Akorn’s “failure to fulfill several closing conditions.” The court agreed that Fresenius validly ended the merger agreement because Akorn’s regulatory compliance representations were false. On this news, Akorn’s shares plummeted over 58% to $5.36.